Analyst Price Targets — DOCS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 20, 2026 11:35 am | — | Piper Sandler | $42.00 | $25.23 | TheFly | Doximity price target raised to $42 from $40 at Piper Sandler |
| February 9, 2026 5:22 am | Richard Close | Canaccord Genuity | $34.00 | $27.73 | StreetInsider | Canaccord Genuity Upgrades Doximity Inc (DOCS) to Buy |
| February 6, 2026 5:19 pm | — | KeyBanc | $38.00 | $27.09 | TheFly | Doximity price target lowered to $38 from $60 at KeyBanc |
| February 6, 2026 2:30 pm | Jailendra Singh | Truist Financial | $37.00 | $25.49 | TheFly | Doximity price target lowered to $37 from $62 at Truist |
| February 6, 2026 1:50 pm | — | Goldman Sachs | $34.00 | $24.93 | TheFly | Doximity price target lowered to $34 from $46 at Goldman Sachs |
| February 6, 2026 1:39 pm | — | Morgan Stanley | $49.00 | $24.61 | TheFly | Doximity price target lowered to $49 from $65 at Morgan Stanley |
| February 6, 2026 1:14 pm | — | BMO Capital | $25.00 | $24.86 | TheFly | Doximity price target lowered to $25 from $45 at BMO Capital |
| February 6, 2026 12:37 pm | David Larsen | BTIG | $50.00 | $33.32 | TheFly | Doximity price target lowered to $50 from $80 at BTIG |
| February 6, 2026 12:15 pm | Scott Berg | Needham | $55.00 | $33.32 | TheFly | Doximity price target lowered to $55 from $75 at Needham |
| February 6, 2026 11:44 am | Jessica Tassan | Piper Sandler | $40.00 | $33.32 | TheFly | Doximity price target lowered to $40 from $70 at Piper Sandler |
Latest News for DOCS
Doximity, Inc. (NYSE: DOCS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average
Doximity stock has fallen during the software stock bust in 2026. The business is doing well, is highly profitable, and has a lock on the doctor social media market in the United States.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Doximity remains a Hold as growth visibility weakens and NRR declines to 112%, raising concerns over future expansion. Engagement and profitability are robust, with workflow tools reaching 720,000 unique prescribers and GAAP gross margin near 90%. DOCS boasts a strong balance sheet, $735 million in cash, no debt, and ongoing share repurchases, supporting downside protection.
Allianz Asset Management GmbH acquired a new stake in Doximity, Inc. (NASDAQ: DOCS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 78,250 shares of the company's stock, valued at approximately $5,724,000. Several other institutional investors have also added to or
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DOCS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.